Bought by GSK under the leadership of Walmsley’s predecessor, Sir Andrew Witty, the business makes protein bars, drinks and powders and is best known for its Maximuscle products for weight training.

GlaxoSmithKline's COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), ahead of what chief executive ...